Trybe Labs was a US laboratory testing services business collecting real blood at home with FDA-approved pain-free device without fingersticks.
What is the investment case, and what must be true for it to hold?
Trybe Labs' acquired testing capability had a plausible integration case because Hims & Hers later packaged lab tests into annual plans, though realizing that case turned on customer uptake rather than any measured adoption. Sigmund NJ, LLC, marketed as Trybe Labs, was a laboratory testing services business located in the United States. Hims & Hers' Labs Base plan included one yearly blood draw with 50 biomarker tests across 9 categories and was available for $199 a year.
Hims & Hers' Labs Advanced plan offered two yearly blood draws spanning over 120 biomarker tests in 10 key categories at $499 a year, and the Labs app provided an analysis for each health category. Quest Mobile charged a $99 in-home collection fee that health insurance did not cover.
Which risks could break the thesis, and what would warn of them?
Trybe Labs' results-and-lifestyle model was exposed to interpretation risk when consumers lacked guidance: the app placed blood-test results and lifestyle recommendations directly in consumers' hands, and without proper guidance, people ordering their own laboratory tests may have misused tests or misinterpreted results.
Hims & Hers paired Labs results with doctor-developed action plans, lifestyle guidance, and access to personalized treatment plans when a healthcare provider deemed them appropriate.
What does the product do for its buyer, and how is it delivered?
Through its app, Trybe Labs provided blood-test results and customized health and wellness plans built on lifestyle recommendations and daily tracking.
The app tracked moods, pain, meals, workouts, sleep quality, stress-reducing activities and nutritional supplements. It integrated with Google Fit and Fitbit to import steps, sleep, blood pressure and other data from tracking devices.